HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar reiterated a Buy rating on Purple Biotech (NASDAQ:PPBT) and maintained a $10 price target.
April 26, 2024 | 6:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Purple Biotech with a $10 price target.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards PPBT, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100